MY190016A - Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone - Google Patents

Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone

Info

Publication number
MY190016A
MY190016A MYPI2017703447A MYPI2017703447A MY190016A MY 190016 A MY190016 A MY 190016A MY PI2017703447 A MYPI2017703447 A MY PI2017703447A MY PI2017703447 A MYPI2017703447 A MY PI2017703447A MY 190016 A MY190016 A MY 190016A
Authority
MY
Malaysia
Prior art keywords
chlorthalidone
losartan
amlodipine
complex formulation
pharmaceutical complex
Prior art date
Application number
MYPI2017703447A
Inventor
Yong Il Kim
Ho Taek Im
Leedong Roh
Youngsu Yoon
Jae Hyun Park
Jong Soo Woo
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of MY190016A publication Critical patent/MY190016A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention provides a pharmaceutical complex formulation comprising a first mixture including amlodipine and chlorthalidone and a second mixture including losartan, which has an improved dissolution and stability. The complex formulation according to the present invention may achieve improved preventive or therapeutic effects for cardiovascular diseases by actuating different mechanism of amlodipine, losartan and chlorthalidone, and exhibits high dissolution rates of amlodipine, losartan and chlorthalidone and improved storage stability, due to the minimized drug interactions, and therefore, it is useful in the fields of pharmaceuticals and medicine.
MYPI2017703447A 2015-03-31 2016-03-11 Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone MY190016A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020150045645A KR101914930B1 (en) 2015-03-31 2015-03-31 Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone
PCT/KR2016/002437 WO2016159535A1 (en) 2015-03-31 2016-03-11 Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone

Publications (1)

Publication Number Publication Date
MY190016A true MY190016A (en) 2022-03-22

Family

ID=57007292

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2017703447A MY190016A (en) 2015-03-31 2016-03-11 Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone

Country Status (11)

Country Link
KR (1) KR101914930B1 (en)
CN (1) CN108289850B (en)
AR (1) AR105758A1 (en)
JO (1) JO3461B1 (en)
MX (1) MX386331B (en)
MY (1) MY190016A (en)
PH (1) PH12017501769B1 (en)
RU (1) RU2713883C2 (en)
TW (1) TWI714560B (en)
UY (1) UY36595A (en)
WO (1) WO2016159535A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101910902B1 (en) * 2016-11-03 2018-10-24 한미약품 주식회사 Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone
KR102912130B1 (en) * 2016-11-11 2026-01-14 주식회사유한양행 A pharmaceutical composition in a monolithic matrix tablet form comprising chlorthalidone or its salt and amlodipine or its salt and a process for preparing the same
KR102943466B1 (en) * 2019-06-17 2026-03-25 주식회사유한양행 A pharmaceutical composition in a multi-layered tablet form comprising amlodipine or its salt and chlorthalidone its salt
KR102900997B1 (en) 2019-12-11 2025-12-22 한미약품 주식회사 Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone
KR20210152943A (en) 2020-06-09 2021-12-16 한미약품 주식회사 Pharmaceutical combination preparation for the prevention or treatment of cardiovascular diseases including amlodipine, losartan and chlorthalidone in a single layer tablet

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5138069A (en) 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
AU685898B2 (en) 1993-12-23 1998-01-29 Du Pont Merck Pharmaceutical Company, The Polymorphs of losartan and the process for the preparation of form II of losartan
KR100452491B1 (en) 2001-03-29 2004-10-12 한미약품 주식회사 A novel crystalline amlodipine camsylate and a preparing method thereof
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
JP2009513543A (en) * 2003-07-16 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Chlorthalidone combination
US20070237815A1 (en) * 2006-04-06 2007-10-11 Lawrence Solomon Dosage forms and methods comprising amlodipine and chlorthalidone
KR101247583B1 (en) * 2006-12-08 2013-03-26 한미사이언스 주식회사 Pharmaceutical composition comprising amlodipine or a pharmaceutically acceptable salt thereof and losartan or a pharmaceutically acceptable salt thereof
KR20090057538A (en) * 2007-12-03 2009-06-08 박사룡 Angiotensin-to-antagonist, calcium antagonist and diuretic therapeutic composition
WO2009084040A1 (en) * 2007-12-28 2009-07-09 Rubicon Research Private Limited Once a day formulation of angiotensin receptor blockers
MA33056B1 (en) 2009-01-23 2012-02-01 Hanmi Holding Co Ltd A solid pharmaceutical formula including amlodipine, losartan and how it is made
KR101907881B1 (en) * 2011-12-30 2018-12-11 한미약품 주식회사 Fixed dose combination formulation comprising losartan, amlodipine and hydrochlorothiazide
KR101392364B1 (en) * 2012-04-17 2014-05-07 한국유나이티드제약 주식회사 Pharmaceutical composition comprising amlodipine and losartan having an improved stability

Also Published As

Publication number Publication date
UY36595A (en) 2016-10-31
RU2017134562A3 (en) 2019-08-15
CN108289850A (en) 2018-07-17
WO2016159535A1 (en) 2016-10-06
PH12017501769B1 (en) 2021-07-02
KR20160117055A (en) 2016-10-10
KR101914930B1 (en) 2018-11-05
AR105758A1 (en) 2017-11-08
RU2713883C2 (en) 2020-02-10
JO3461B1 (en) 2020-07-05
PH12017501769A1 (en) 2018-03-19
RU2017134562A (en) 2019-04-04
CN108289850B (en) 2021-04-09
TW201639563A (en) 2016-11-16
TWI714560B (en) 2021-01-01
MX386331B (en) 2025-03-18
MX2017012459A (en) 2018-01-30

Similar Documents

Publication Publication Date Title
CY1123649T1 (en) IMIDAZOLINE DERIVATIVES, METHODS OF THEIR PREPARATION AND THEIR APPLICATIONS IN MEDICINE
PH12017501769A1 (en) Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone
MX2020010737A (en) Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis b.
EA033544B1 (en) Pyridone derivatives as rearranged during transfection (ret) kinase inhibitors
CR20160275A (en) DERIVATIVES OF SULPHAMOYLPYRROLAMIDE AND USE AS A MEDICINAL PRODUCT FOR THE TREATMENT OF HEPATITIS B
TN2015000278A1 (en) Autotaxin inhibitors
EA201591371A1 (en) Pyridine derivatives as easily degraded inhibitors ROCK
MY195977A (en) Heterocyclic Compounds and uses Thereof
EA033343B1 (en) Compounds inhibiting rip2 kinase, pharmaceutical composition based thereon and use thereof for the treatment of diseases mediated by rip2 kinase
TW201613911A (en) Heterocyclic compounds and uses thereof
TN2017000529A1 (en) New hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them
IN2014DN06501A (en)
NZ729037A (en) Carboxylic acid compound, method for preparation thereof, and use thereof
PH12016500420A1 (en) Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt
MX363843B (en) Pharmaceutical compositions comprising nitroxyl donors.
MA39765A (en) Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use
EA201500112A1 (en) 3-SUBSTITUTED DERIVATIVES ESTRA-1,3,5 (10), 16-TETRAENA, METHODS OF THEIR PRODUCTION, PHARMACEUTICAL MEANS, WHICH CONTAIN THEM, AND THEIR USE FOR RECEPTION OF MEDICINES
MX2018000546A (en) Pharmaceutical composition containing celecoxib and tramadol.
MX2017013636A (en) FIXED DOSE COMBINATION RESISTANT TO HANDLING THAT PROVIDES A QUICK RELEASE OF TWO DRUGS FROM DIFFERENT PARTICLES.
EA201700019A1 (en) HIGHLY PURE ORIENTATION AND METHOD FOR ITS OBTAINING
PH12019500778A1 (en) Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone
WO2016040462A3 (en) Formulations and methods for treatment of metabolic syndrome
IN2015DN02999A (en)
BR112018068370A2 (en) fixed dose pharmaceutical composition containing amlodipine, candesartan cilexetil and hydrochlorothiazide for the treatment of hypertension
MX2017013633A (en) Tamper-resistant fixed dose combination providing fast release of two drugs from particles.